Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04130919 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT04130919 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 19 participants.
The verdict
NCT04130919, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The primary objective of this study is to demonstrate the efficacy of tilpisertib (formerly GS-4875) compared with placebo control in achieving clinical remission per modified Mayo Clinic Score (MCS) in adults with moderately to severely active ulcerative colitis (UC).
Interventions
- DRUG Placebo
- DRUG Tilpisertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-12-20 |
| Est. Completion | 2021-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04130919
The ClinicalTrials.gov registry entry for NCT04130919 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04130919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04130919 about?
NCT04130919 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis". The primary objective of this study is to demonstrate the efficacy of tilpisertib (formerly GS-4875) compared with placebo control in achieving clinical remission per modified Mayo Clinic Score (MCS) in adults with moderately to severely active ulcerative colitis (UC).
What is the current status of trial NCT04130919?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2019-12-20. Estimated completion is 2021-12-14.
What interventions are being tested in trial NCT04130919?
The interventions under investigation include: Placebo (DRUG), Tilpisertib (DRUG).
Who is sponsoring clinical trial NCT04130919?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.